Dl-Penicillamine

Dl-Penicillamine

SCHEMBL22124997

CC(C)(S)C(N)C(=O)O.NC(CS)C(=O)O

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.72
ALDH1A1 P00352 2/20 0.72
MAPT P10636 1/20 0.72
SLC7A11 Q9UPY5 1/20 0.64
SLC7A5 Q01650 1/20 0.39
ENPEP Q07075 4/20 0.38
GRIK1 P39086 5/20 0.38
SLC1A2 P43004 6/20 0.35
SLC1A3 P43003 5/20 0.35
SLC1A1 P43005 5/20 0.35
GRIK2 Q13002 3/20 0.34
GRM8 O00222 1/20 0.34
GRM6 O15303 1/20 0.34
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GSR P00390 1/20 0.34
CYP1A2 P05177 1/20 0.34
GRM5 P41594 1/20 0.34
GRIA1 P42261 1/20 0.34
GRIA2 P42262 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Penicillamine SCHEMBL7170074 1.00 PTGS1 (0.72) PTGS1ALDH1A1MAPTSLC7A11SLC7A5
Dl-Penicillamine SCHEMBL4261009 1.00 PTGS1 (0.72) PTGS1ALDH1A1MAPTSLC7A11SLC7A5
Penicillamine SCHEMBL22124996 1.00 PTGS1 (0.72) PTGS1ALDH1A1MAPTSLC7A11SLC7A5
Penicillamine SCHEMBL11222229 0.98 PTGS1 (0.69) PTGS1ALDH1A1MAPTSLC7A11SLC7A5
Dl-Penicillamine SCHEMBL159653 0.85 ALDH1A1 (1.00) PTGS1ALDH1A1MAPTSLC7A11SLC7A5
Dl-Penicillamine SCHEMBL22322162 0.85 ALDH1A1 (1.00) PTGS1ALDH1A1MAPTSLC7A11SLC7A5
Dl-Penicillamine SCHEMBL4344 0.85
Dl-Penicillamine SCHEMBL57527 0.85
Penicillamine SCHEMBL129296 0.85 ALDH1A1 (1.00) PTGS1ALDH1A1MAPTSLC7A11SLC7A5
Penicillamine SCHEMBL603349 0.85 ALDH1A1 (1.00) PTGS1ALDH1A1MAPTSLC7A11SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4041217-A1 A PHARMACEUTICAL COMPOSITION COMPRISING CANNABINOID Blackhawk Partners Ltd. (CY) 2022-08-17 EP claimed
WO-2021198041-A1 A PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYCHLOROQUINE, CHLOROQUINE, OR METABOLITE THEREOF BLACKHAWK PARTNERS LIMITED (CY) 2021-10-07 WO claimed
WO-2021069576-A1 A PHARMACEUTICAL COMPOSITION COMPRISING CANNABINOID BLACKHAWK PARTNERS LTD (CY) 2021-04-15 WO claimed
US-20230100385-A1 Pharmaceutical Composition Comprising Cannabinoid BLACKHAWK PARTNERS LTD (CY) 2023-03-30 US disclosed
EP-4041217-A1 A PHARMACEUTICAL COMPOSITION COMPRISING CANNABINOID Blackhawk Partners Ltd. (CY) 2022-08-17 EP disclosed
EP-4041217-A1 A PHARMACEUTICAL COMPOSITION COMPRISING CANNABINOID Blackhawk Partners Ltd. (CY) 2022-08-17 EP disclosed
EP-3897849-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR PD-L1 BicycleTx Limited (GB) 2021-10-27 EP disclosed
WO-2021198041-A1 A PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYCHLOROQUINE, CHLOROQUINE, OR METABOLITE THEREOF BLACKHAWK PARTNERS LIMITED (CY) 2021-10-07 WO disclosed
WO-2021198041-A1 A PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYCHLOROQUINE, CHLOROQUINE, OR METABOLITE THEREOF BLACKHAWK PARTNERS LIMITED (CY) 2021-10-07 WO disclosed
WO-2021069576-A1 A PHARMACEUTICAL COMPOSITION COMPRISING CANNABINOID BLACKHAWK PARTNERS LTD (CY) 2021-04-15 WO disclosed
WO-2021069576-A1 A PHARMACEUTICAL COMPOSITION COMPRISING CANNABINOID BLACKHAWK PARTNERS LTD (CY) 2021-04-15 WO disclosed
US-20210106636-A1 PHARMACEUTICAL COMPOSITION COMPRISING CANNABINOID BLACKHAWK PARTNERS LTD (CY) 2021-04-15 US disclosed
WO-2020128526-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR PD-L1 BICYCLETX LIMITED (GB) 2020-06-25 WO disclosed
CN-1835740-A Pharmaceutical composition for preventing breast cancer and ovarian cancer POMERANIAN ACADEMY OF MEDICINE (PL) 2006-09-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230100385-A1 Pharmaceutical Composition Comprising Cannabinoid CNR2, CNR1, GSR PTGS1 107/4885ALDH1A1 1591/4885MAPT 819/4885
US-20210106636-A1 PHARMACEUTICAL COMPOSITION COMPRISING CANNABINOID CNR2, CNR1, GSR PTGS1 107/4885ALDH1A1 1591/4885MAPT 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.